Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
09 August 2023Website:
http://neuraxis.comNext earnings report:
N/ALast dividends:
N/ANext dividends:
N/APrice
regular market | Wed, 20 Nov 2024 14:30:00 GMTDividend
Analysts recommendations
Institutional Ownership
NRXS Latest News
NeurAxis, Inc (NYSE:NRXS ) Q3 2024 Results Conference Call November 12, 2024 9:00 AM ET Company Participants Ben Shamsian - Investor Relations Brian Carrico - Chief Executive Officer Tim Henrichs - Chief Financial Officer Operator Good day, and thank you for standing by. Welcome to the NeurAxis's Third Quarter 2024 Financial Results Conference Call.
NRXS reports strong third-quarter results with rising revenues, reduced losses and expanded insurance coverage, driving its stock to outperform the market.
Conference call will be held today, Tuesday, November 12 at 9:00 am ET Conference call will be held today, Tuesday, November 12 at 9:00 am ET
Discover why Zacks rates NeurAxis as "Neutral", being the first on Wall Street to initiate coverage on the stock. Explore NRXS' promising growth prospects and financial health amid market challenges.
CARMEL, Ind., Sept. 19, 2024 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in children and adults, will participate in a webcasted presentation and host one-on-one meetings with investors at the Lytham Partners Fall 2024 Investor Conference, taking place virtually on Tuesday, October 1, 2024.
CARMEL, Ind., Aug. 13, 2024 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in children and adults, today announced medical policy coverage for Percutaneous Electrical Nerve Field Stimulation (PENFS), for Blue Cross Blue Shield (BCBS) of Vermont Medical Members, effective 10/1/2024. This medical policy will bring our national total coverage for PENFS to roughly 23 million, with more decisions from major payers still pending.
NeurAxis, Inc. (NYSE:NRXS ) Q2 2024 Earnings Conference Call August 9, 2024 9:00 AM ET Company Participants Ben Shamsian - Investor Relations Brian Carrico - Chief Executive Officer Tim Henrichs - Chief Financial Officer Conference Call Participants Mark Foster - Kirr Marbach & Co Operator Good day and thank you for standing by. Welcome to NeurAxis Reports Second Quarter 2024 Financial Results.
Carmel, Ind., Aug. 09, 2024 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies for chronic and debilitating conditions in children and adults, today announced results for the second quarter period ended June 30, 2024.
CARMEL, Ind., June 07, 2024 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in children and adults, today announced a submission to the FDA for expansion of its IB-Stim label. The new submission is significant as it would allow access to a larger patient population beyond 11-18 years of age and allow for marketing of 4 devices per prescription.
NeurAxis, Inc. (NYSE:NRXS ) Q1 2024 Earnings Conference Call May 22, 2024 9:00 AM ET Company Participants Ben Shamsian - Investor Relations Brian Carrico - Chief Executive Officer Tim Henrichs - Chief Financial Officer Operator Good day, and thank you for standing by. Welcome to NeurAxis Reports First Quarter 2024 Financial Results.
What type of business is NeurAxis?
NeurAxis, Inc., a medical technology company, focuses on developing neuromodulation therapies to address chronic and debilitating conditions in children and adults in the United States. It offers IB-Stim, a percutaneous electrical nerve field stimulation system intended to be used in patients 11-18 years of age with functional abdominal pain associated with irritable bowel syndrome. The company sells its products to healthcare companies, including hospitals and clinics. The company was formerly known as Innovative Health Solutions, Inc. and changed its name to NeurAxis, Inc. in March 2022. The company was founded in 2011 and is headquartered in Carmel, Indiana.
What sector is NeurAxis in?
NeurAxis is in the Healthcare sector
What industry is NeurAxis in?
NeurAxis is in the Biotechnology industry
What country is NeurAxis from?
NeurAxis is headquartered in United States
When did NeurAxis go public?
NeurAxis initial public offering (IPO) was on 09 August 2023
What is NeurAxis website?
https://neuraxis.com
Is NeurAxis in the S&P 500?
No, NeurAxis is not included in the S&P 500 index
Is NeurAxis in the NASDAQ 100?
No, NeurAxis is not included in the NASDAQ 100 index
Is NeurAxis in the Dow Jones?
No, NeurAxis is not included in the Dow Jones index
When was NeurAxis the previous earnings report?
No data
When does NeurAxis earnings report?
Next earnings report date is not announced yet